
Introducing the Edwards PASCAL Transcatheter Valve Repair System

Empowering and effective MR reduction that respects the native anatomy



Driven by a passion to help patients.

With over 60 years of experience in creating new therapies and procedures that elevate care in meaningful ways, Edwards Lifesciences is the global leader in patient-focused medical innovations.

For more information, please visit www.Edwards.com/PASCAL or contact us at pascal_info@edwards.com

Reference

- 1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study
- 2. Goel SS, Bajaj N, Aggarwal B, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure: comprehensive analysis to determine the potential role of MitraClip for this unmet need.
- 3. Praz F, Spargias K, Chrissoheris M et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. *Lancet*. 2017;390(10096):773-780.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, and PASCAL are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.


 $\hbox{@ 2019 Edwards Lifesciences Corporation. All rights reserved. E8830/01-19/TMTT}$

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Empowering. Effective. Safe.

Transform the way you see mitral valve repair




Introducing the CE Mark approved Edwards PASCAL Transcatheter Valve Repair System



Mitral regurgitation: complex disease with limited options

Mitral regurgitation (MR) occurs in approximately 2% of the population, with up to 10% of people over 75 years old affected¹

Medically managed patients with severe MR have poor outcomes²:






Introducing the PASCAL Repair System

An empowering transcatheter mitral valve repair system that effectively reduces MR while respecting the native anatomy

- Enables optimised leaflet capture
- Designed for effective MR reduction³
- Helps promote procedural safety








Optimised leaflet capture

Empowering Edwards delivery system with direct manoeuvring in three planes to improve procedural efficiency



Broad paddles create a wide capture area for simplified leaflet capture



Independent leaflet capture supports gentle interaction and enables operators to capture leaflets in difficult pathologies



Designed for effective mitral regurgitation reduction³

Helps deliver the desired outcomes while respecting the native anatomy



leaflet coaptation



Excellent safety profile

Contoured paddles and a unique central spacer are designed to reduce leaflet stress while implant elongation helps promote safe subvalvular manoeuvring

